Skip to main content
SpringerLink
Log in

Hormonosensibilité des cancers ovariens épithéliaux

  • Chapter
Les cancers ovariens

Part of the book series: Abord clinique ((ONCOLPRAT))

  • 328 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Rao BR, Slotman BJ (1991) Endocrine factors in common epithelial ovarian cancer. Endocr Rev 21: 14–26

    Google Scholar 

  2. Weiss NS, Lyon JL, Krishnamurthy S et al. (1982) Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68: 95–8

    CAS  PubMed  Google Scholar 

  3. Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592–8

    CAS  PubMed  Google Scholar 

  4. Purdie D, Green A, Bain C et al. (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women’s Health Study Group. Int J Cancer 62: 678–84

    CAS  PubMed  Google Scholar 

  5. Hempling RE, Wong C, Piver MS et al. (1997) Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89: 1012–16

    Article  CAS  PubMed  Google Scholar 

  6. Purdie DM, Bain CJ, Siskind V et al. (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81: 559–63

    Article  CAS  PubMed  Google Scholar 

  7. Parazzini F, La Vecchia C, Negri E, Villa A (1994) Estrogen replacement therapy and ovarian cancer risk. Int J Cancer 57: 135–6

    CAS  PubMed  Google Scholar 

  8. Riman T, Dickman PW, Nilsson S et al. (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol Aug 15 156(4): 363–73

    Google Scholar 

  9. Risch HA (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63: 254–7

    Article  CAS  PubMed  Google Scholar 

  10. Hunt K, Vessey M, McPherson K, Coleman M (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94: 620–35

    CAS  PubMed  Google Scholar 

  11. Adami HO, Persson I, Hoover R et al. (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44: 833–9

    CAS  PubMed  Google Scholar 

  12. Rodriguez C, Calle EE, Coates RJ et al. (1995) Estrogen replacement therapy and fetal ovarian cancer. Am J Epidemiol 141: 828–35

    CAS  PubMed  Google Scholar 

  13. Rodriguez C, Patel AV, Calle EE et al. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460–5

    CAS  PubMed  Google Scholar 

  14. Lacey JV Jr, Mink PJ, Lubin JH et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288: 334–41

    Article  CAS  PubMed  Google Scholar 

  15. Anderson GL, Judd HL, Kaunitz AM et al. (2003) Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. Oct 1 290(13): 1739–48

    Article  CAS  PubMed  Google Scholar 

  16. Beral V, Banks E, Reeves G, Appleby P (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4: 191–210

    CAS  PubMed  Google Scholar 

  17. Makar AP (2000) Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer. Jun; 7(2): 85–93

    Article  CAS  PubMed  Google Scholar 

  18. Quinn M A (1987), Hormonal therapy of ovarian cancer. In: Sharp F and Soutter W P (eds) Ovarian cancer: the way ahead, Royal College of Obstetricians and Gynaecologists, London 383–93

    Google Scholar 

  19. Rolski J, Pawlicki M (1998) Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Ginekol Pol 69: 586–89

    CAS  PubMed  Google Scholar 

  20. Marth C, Sorheim N, Kaern J et al. (1997) Trope, Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 7: 256–61

    Article  Google Scholar 

  21. Schwartz PE, Keating G, MacLusky N, Naftolin F et al. (1982) Eisenfeld, Tamoxifen therapy for advanced epithelial ovarian cancer. Obstet Gynecol 59: 583–7

    CAS  PubMed  Google Scholar 

  22. Landoni F, Epis A, Gorga G et al. (1985) Hormonal treatment in advanced epithelial ovarian cancer. In: Pamutti F (ed) Anti-oestrogen in Oncology. Past, Present and Prospects, Excerpta Medica, Amsterdam, New York, Oxford: 262–5

    Google Scholar 

  23. Shirey DR, Kavanagh JJ, Gershenson DM et al. (1985) Tamoxifen, therapy of epithelial ovarian cancer. Obstet Gynecol 66: 575–851

    CAS  PubMed  Google Scholar 

  24. Slevin ML, Harvey VJ, Osborne RJ et al. (1987) A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 22: 309–12

    Google Scholar 

  25. Weiner SA, Alberts DS, Surwitt EA et al. (1987) Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 27: 208–13. Abstract

    Article  CAS  PubMed  Google Scholar 

  26. Belinson JL, McClure M, Badger G (1987) Randomized trial of megestrol acetate vs megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 28: 151–5

    Article  CAS  PubMed  Google Scholar 

  27. Markman M, Iseminger KA, Hatch KD et al. (1996) Tamoxifen in platinum-refractory ovarian cancer. A Gynecologic Oncology Group ancillary report. Gyncol Oncol 62: 4–6. Abstract PDF (54 K)

    CAS  Google Scholar 

  28. Hatch KD, Beecham JB, Blessing JA, Creasman WT (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 68: 269–72

    CAS  PubMed  Google Scholar 

  29. Osborne RJ, Malik ST, Slevin ML et al. (1988) Tamoxifen in refractory ovarian can-cer. The use of a loading dose schedule. Br J Cancer 57: 115–6. Abstract-EMBASE Abstract-MEDLINE

    CAS  PubMed  Google Scholar 

  30. Pagel J, Rose C, Thorpe S, Hald I (1983) Treatment of advanced ovarian carcinoma with tamoxifen. A phase II trial. Proc 2nd Eur Conf Clin Oncol 42 (Abstracts)

    Google Scholar 

  31. Hammerlynck JVTH, Vermorken JB, Van der Burg MEL (1985) Phase II study of tamoxifen in advanced ovarian cancer. Proc 3rd Eur Conf Clin Oncol 43 (Abstract)

    Google Scholar 

  32. Cambell JJ, Rome RM, Quinn MA et al. (1984) Tamoxifen for recurrent progressive epithelial ovarian tumours. Proc XI Clin Oncol Soc Australia 73 (Abstract)

    Google Scholar 

  33. Jakobsen A, Bertelsen K, Sell A (1987) Cyclic hormonal treatment in ovarian cancer. A phase II trial. Eur J Cancer Clin Oncol 23: 915–6. Abstract-EMBASE Abstract-MEDLINE

    Article  CAS  PubMed  Google Scholar 

  34. Ahlgren JD, Ellison NM, Gottlieb RJ et al. (1993) Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 11: 1957–68. Abstract-EMBASE Abstract-MEDLINE

    CAS  PubMed  Google Scholar 

  35. Jager W, Sauerbrei W, Beck E et al. (1995) A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 15: 2639–42. Abstract-EMBASE Abstract-MEDLINE

    CAS  PubMed  Google Scholar 

  36. Van Der Velden J, Gitsch G, Wain G et al. (1995) Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gyncol Cancer 5: 301–5. Abstract-Elsevier BIOBASE

    Google Scholar 

  37. Gennatas C, Dardoufas C, Karvouni H et al. (1996) Phase II trial of tamoxifen in patients with advanced epithelial ovarian cancer. Am Soc Clin Oncol 15: 287 (Abstract 782)

    Google Scholar 

  38. Trope C, Marth C, Kaern J (2000) Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer. Sep 36Suppl 4: S59–61

    CAS  PubMed  Google Scholar 

  39. Perez-Gracia JL, Carrasco EM (2002) Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol. Feb 84(2): 201–9

    Article  CAS  PubMed  Google Scholar 

  40. Bowman A, Gabra H, Langdon SP et al. (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Can Res 8: 2233–9

    CAS  Google Scholar 

  41. Papadimitriou CA, Markaki S, Siapkaras J et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66(2): 112–7

    Article  CAS  PubMed  Google Scholar 

  42. Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. Gynecol Oncol. Jul 94(1): 25–32

    CAS  Google Scholar 

  43. Cunat S, Rabenoelina F, Daurès JP et al. (2005) Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol. In press Feb

    Google Scholar 

  44. Langdon SP, Hirst GL, Miller EP et al. (1994) The regulation of growth and protein ex-pression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 50: 131–5

    Article  CAS  PubMed  Google Scholar 

  45. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75: 1497–502

    Article  CAS  PubMed  Google Scholar 

  46. Nash JD, Ozols RF, Smyth JF, Hamilton TC (1989) Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 73: 1009–16

    CAS  PubMed  Google Scholar 

  47. Hayashido Y, Lucas A, Rougeot C et al. (1998) Estradiol and fibulin-1 inhibit motility of human ovarian-and breast-cancer cells induced by fi-bronectin. Int J Cancer 75: 654–8

    Article  CAS  PubMed  Google Scholar 

  48. Bardin A, Hoffman P, Boulle N et al. (2004) Involvement of ER beta in ovarian carcinogenesis. Cancer Res, Aug 15, 64(16): 5861–9

    Article  CAS  PubMed  Google Scholar 

  49. Chu S, Mamers P, Burger HG, Fuller PJ (2000) Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 85: 1200–5

    Article  CAS  PubMed  Google Scholar 

  50. Hillier SG, Anderson RA, Williams AR, Tetsuka M (1998) Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Mol Hum Reprod 4: 811–5

    Article  CAS  PubMed  Google Scholar 

  51. Pujol P, Rey JM, Nirde P et al. (1998) Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58: 5367–73

    CAS  PubMed  Google Scholar 

  52. Kuiper GGJM, Gustafsson JA (1997) The novel oestrogen receptor-beta subtype: potential role in the cell-and promoter-specific actions of oestrogens and anti-oestrogens. FEBS Lett 23 410: 87–90

    CAS  Google Scholar 

  53. Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterisation of a novel human estrogen receptor. FEBS Lett 392: 49–53

    Article  CAS  PubMed  Google Scholar 

  54. Brandenberger AW, Tee MK, Jaffe RB (1998) Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian can-cer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83: 1025–28

    Article  CAS  PubMed  Google Scholar 

  55. Bardin A, Boulle N, Lazennec G et al. (2004) Loss of ER beta as a common step of estrogen dependant tumor progression. Endocrine Related Cancer. Sept 2, 11: 1–15

    Article  Google Scholar 

  56. van Doorn HC, Burger CW, van der Valk P, Bonfrer HM (2000) Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol 53: 201–5

    PubMed  Google Scholar 

  57. Nunez AM, Jakowlev S, Briand JP et al. (1987) Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121: 1759–65

    CAS  PubMed  Google Scholar 

  58. Wysocki SJ, Hahnel E, Masters A et al. (1990) Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 50: 1800–2

    CAS  PubMed  Google Scholar 

  59. Henry JA, Bennet MK, Piggott NH et al. (1991) Expression of the pNR-2pS2 protein in diverse human epithelial tumors. Br J Cancer 64: 677–82

    CAS  PubMed  Google Scholar 

  60. Watson PH, Pon RT, Shiu RP (1991) Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996–4000

    CAS  PubMed  Google Scholar 

  61. Schuchard M, Landers JP, Sandhu NP, Spelsberg TC (1993) Steroid hormone regulation of nuclear proto-oncogenes. Endocr Rev 14: 659–69

    Article  CAS  PubMed  Google Scholar 

  62. Baker VV, Borst MP, Dixon D et al. (1990) c-myc amplification in ovarian cancer. Gynecol Oncol 38: 340–2

    Article  CAS  PubMed  Google Scholar 

  63. Schreiber G, Dubeau L (1990) C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am J Pathol 137: 653–8

    CAS  PubMed  Google Scholar 

  64. Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–12

    CAS  PubMed  Google Scholar 

  65. Haldane JS, Hird V, Hughes CM, Gullick WJ (1990) c-erbB-2 oncogene expression in ovarian cancer. J Pathol 162: 231–7

    Article  CAS  PubMed  Google Scholar 

  66. Berchuck A, Kamel A, Whitaker R et al. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–91

    CAS  PubMed  Google Scholar 

  67. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS (1990) Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–51

    CAS  PubMed  Google Scholar 

  68. Hua W, Christianson T, Rougeot C et al. (1995) SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 55: 279–89

    Article  CAS  PubMed  Google Scholar 

  69. Clinton GM, Rougeot C, Derancourt J et al. (1996) Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci USA 93: 316–20

    Article  CAS  PubMed  Google Scholar 

  70. Moll F, Katsaros D, Lazennec G et al. (2002) Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21: 1097–107

    Article  CAS  PubMed  Google Scholar 

  71. Roger P, Pujol P, Lucas A et al. (1998) Increased immunostaining of fibulin-1, an estrogenregulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol. 153:1579–88

    CAS  PubMed  Google Scholar 

  72. Bardin A, Moll F, Margueron R et al. (2004) Transcriptional and post-transcriptional regulation of fibulin-1 by estrogens leads to differential induction of mRNA variants in ovarian and breast cancer cells. Endocrinology. Nov 4

    Google Scholar 

  73. Rochefort H, Garcia M, Glondu M et al. (2000) Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta Feb 15; 291(2): 157–70

    Article  CAS  PubMed  Google Scholar 

  74. Scambia G, Panici PB, Ferrandina G et al. (1991) Cathep-sin D assay in ovarian cancer: correlation with pathological features and receptors for estro-gen, progesterone and epidermal growth factor. Br J Cancer 64: 182–4

    CAS  PubMed  Google Scholar 

  75. Scambia G, Panici PB, Ferrandina G et al. (1994) Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 30: 935–40

    Article  Google Scholar 

  76. Yousef GM, Diamandis EP (2002) Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol 27: 157–66

    CAS  PubMed  Google Scholar 

  77. Dong Y, Kaushal A, Bui L et al. (2001) Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7: 2363–71

    CAS  PubMed  Google Scholar 

  78. Anzick SL, Kononen J, Walker RL et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965–8

    Article  CAS  PubMed  Google Scholar 

  79. Tanner MM, Grenman S, Koul A et al. (2000) Frequent amplification of chromosomal region 20q12–q13 in ovarian cancer. Clin Cancer Res 6: 1833–9

    CAS  PubMed  Google Scholar 

  80. Glaeser M, Floetotto T, Hanstein B et al. (2001) Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res 33: 121–6

    Article  CAS  PubMed  Google Scholar 

  81. Antoniou A, Pharoah PD, Narod S et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May; 72(5): 1117–30.

    Article  CAS  PubMed  Google Scholar 

  82. Pujol P, This P, Noruzinia M et al. (2004) Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens? Bull Cancer. Jul-Aug; 91(7–8): 583–91

    CAS  PubMed  Google Scholar 

  83. Fan S, Wang J, Yuan R et al. (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354–6

    Article  CAS  PubMed  Google Scholar 

  84. Havrilesky LJ, McMahon CP, Lobenhofer EK et al. (2001) Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J Soc Gynecol Investig 8: 104–13

    CAS  PubMed  Google Scholar 

  85. Merajver SD, Pham TM, Caduff RF et al. (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9: 439–43

    Article  CAS  PubMed  Google Scholar 

  86. Okubo T, Mok SC, Chen S (2000) Regulation of aromatase expression in human ovarian surface epithelial cells. J Clin Endocrinol Metab 85: 4889–99

    Article  CAS  PubMed  Google Scholar 

  87. Hinshelwood MM, Smith ME, Murry BA, Mendelson CR (2000) A 278 bp region upstream of the human CYP19 (aromatase) gene mediates ovary-specific expression in transgenic mice. Endocrinology 141: 2050–3

    Article  CAS  PubMed  Google Scholar 

  88. Thompson MA, Adelson MD, Kaufman LM et al. (1988) Aromatisation of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma. Cancer Res 48: 6491–7

    CAS  PubMed  Google Scholar 

  89. Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial and ovarian malignancies. Endocr Rev Oct 19: 593–607

    Google Scholar 

  90. Zimniski SJ, Garola RE, Fendl K, Peterson CM (1989) Endocrine characterisation of a human ovarian carcinoma (BG-1) established in nude mice. Steroids 54: 593–606

    Article  CAS  PubMed  Google Scholar 

  91. Blompquist CH, Leung BS, Zhang R et al. (1995) Properties and regulation of 17 betahydroxysteroid oxidoreductase of OVCAR-3, CAOV-3 and A431 cells: effects of epidermal growth factor, estradiol, estradiol and progesterone. J Cell Biochem 59: 409–17

    Google Scholar 

Download references

Authors
  1. P. Pujol
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Pujol, P. (2006). Hormonosensibilité des cancers ovariens épithéliaux. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_4

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation